Lipocine misses Q1 EPS estimates; LPCN 1154 PPD Phase 3 fails primary endpoint

Lipocine Inc.

2026-Q1 EPS reported -$0.54 revenue$119,397

Net loss of $3.7M ($0.52/share) vs $1.9M loss ($0.35) in Q1 2025; cash $24.7M.
Phase 3 trial of LPCN 1154 for postpartum depression missed primary endpoint; HAM-D reduction vs placebo not significant at hour 60.
LPCN 1154 well-tolerated; no serious AEs, sedation, or loss of consciousness; post hoc significance in patients with psychiatric history (n=54).
Company applied for breakthrough/fast track designations for LPCN 1154; evaluating validation study or strategic options.
TLANDO royalty revenue $119K in Q1 2026 versus $94K in prior year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lipocine Inc. reported First Quarter Ended March 31, 2026 results: net income net loss of $3.7 million, EPS ($0.52) per diluted share.

Period: First Quarter Ended March 31, 2026
Net income: net loss of $3.7 million
EPS: ($0.52) per diluted share
Result: reported results

Exact text from the filing

Lipocine reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of $1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.